Aquila Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Aquila Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$914K	Hold	13,000	–	–	1.02%	36
2024 Q2	$1.07M	Hold	13,000	–	–	1%	45
2024 Q1	$1.14M	Hold	13,000	–	–	0.97%	47
2023 Q4	$1.25M	Buy	13,000 +5,000	+63%	+$442K	1.08%	46
2023 Q3	$708K	Hold	8,000	–	–	0.65%	64
2023 Q2	$693K	Hold	8,000	–	–	0.57%	71
2023 Q1	$778K	Sell	8,000 -3,000	-27%	-$311K	0.64%	64
2022 Q4	$1.14M	Hold	11,000	–	–	0.88%	54
2022 Q3	$932K	Hold	11,000	–	–	0.7%	64
2022 Q2	$912K	Buy	11,000 +3,000	+38%	+$239K	0.65%	66
2022 Q1	$617K	Hold	8,000	–	–	0.35%	79
2021 Q4	$707K	Buy	+8,000	New	+$660K	0.34%	84

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

EIM

Elliott Investment Management West Palm Beach, Florida $22.7B AUM 59.88% 1-Year Est. Return

Aquila Investment Management's BMRN Position: Q3 2024 in Review

Aquila Investment Management held its BioMarin Pharmaceuticals (BMRN) position steady in Q3 2024 at 13,000 shares worth $914K. The position accounts for 1.02% of the portfolio, ranked #36.

Aquila Investment Management first reported a position in BMRN in Q4 2021 and has held it in 12 quarters since. The position peaked at $1.25M in Q4 2023. 554 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.

Aquila Investment Management held 13,000 shares of BioMarin Pharmaceuticals worth $914K as of Q3 2024.
Aquila Investment Management left its BioMarin Pharmaceuticals share count unchanged in Q3 2024.
BioMarin Pharmaceuticals made up 1.02% of Aquila Investment Management's portfolio in Q3 2024, its #36 holding.
Aquila Investment Management first reported a position in BioMarin Pharmaceuticals in Q4 2021 and has held it in 12 quarters since.
Aquila Investment Management's BioMarin Pharmaceuticals position peaked at $1.25M in Q4 2023.
554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.

Based on Aquila Investment Management's 13F filing for Q3 2024, filed 22 Oct 2024.